Researchers are rapidly examining retatrutide, a innovative drug created by Eli Lilly, as a significant breakthrough in body reduction . Different than many earlier approaches, retatrutide is a double -action compound targeting both GLP-1 and GIP, substances that impact hunger and glucose balance